A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer
NUCLEAR MEDICINE COMMUNICATIONS(2024)
关键词
prostate cancer,PSMA-1095,radioligand therapy,radiopharmaceutical
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要